Clinical Edge Journal Scan

Sugar-sweetened beverage intake after breast cancer diagnosis may increase mortality


 

Key clinical point : Higher sugar-sweetened beverages (SSB) consumption after a breast cancer diagnosis was associated with greater breast cancer-specific and all-cause mortality.

Major finding: Compared with no consumption, the risk for breast cancer-specific and all-cause mortality increased with increasing consumption of SSB ( Ptrend= .001 and .0001, respectively). The consumption of artificially sweetened beverages was not associated with higher breast cancer-specific or all-cause mortality.

Study details: A prospective cohort of 8,863 women with stages I-III breast cancer who completed a validated food frequency questionnaire every 4 years.

Disclosure: This study was supported by the National Institutes of Health, the American Institute for Cancer Research, and the Breast Cancer Research Foundation. Dr. Holmes received grants, personal fees, and nonfinancial support from various sources outside this work. The remaining authors made no disclosures.

Source: Farvid MS et al. Cancer. 2021 May 4. doi: 10.1002/cncr.33461.

Recommended Reading

Clinical Edge Journal Scan Commentary: Breast Cancer June 2021
MDedge Hematology and Oncology
Breast-conserving surgery tops mastectomy
MDedge Hematology and Oncology
Breast cancer: Routine scans can identify heart disease
MDedge Hematology and Oncology
Immediate breast reconstruction delays radiotherapy and increases complication
MDedge Hematology and Oncology
Pertuzumab plus high-dose trastuzumab shows activity in HER-2-positive breast cancer
MDedge Hematology and Oncology
Early breast cancer: Trastuzumab emtansine shows survival benefit regardless of NACT used
MDedge Hematology and Oncology
Breast cancer: Mortality rates remain high beyond 5 years of diagnosis
MDedge Hematology and Oncology
Breast cancer: Fertility concerns affect endocrine therapy decisions in young survivors
MDedge Hematology and Oncology
Cochrane: PARP inhibitors improve survival in HER2-negative, BRCA-mutated breast cancer
MDedge Hematology and Oncology
Low risk for second breast cancer in older women with radiation alone
MDedge Hematology and Oncology